Sitemap Contact Privacy Statement Imprint

Tools & Data Access

Study of renal cancers and renal cancer metastases
Study ID: EGAS00001001176
Study of primary renal cancers as well as metastases derived from renal cancers in various distant organs.
Cell motility and migration as determinants of stem cell efficacy
Study ID: EGAS00001002478
Limited stem cell migration capacities and undirected homing hamper their therapeutic efficacy. We report here the novel technology to isolate stem cell subpopulations with high migration potential. Hereby, we identified podoplanin-dependent stem cell mobility as important mechanism for their in vivo homing capacities and therapeutic efficacy as validated in preclinical models of Alzheimer´s disease and mouse glioma. In vivo applications of highly migrating stem cells resulted in remarkable improvement of targeted homing and engraftment rates. Moreover, animals receiving highly migrating stem cells showed higher recovery rates compared to unselected stem cells. This novel technology provides useful tool to improve therapeutic efficacy of stem cells and give insights into stem cell subpopulations heterogeneity with the potential of general applicability for cellular therapies.
Panel-based next-generation sequencing study of human liver samples
Study ID: EGAS00001003426
Panel-based next-generation sequencing study of 150 human surgical liver samples from Caucasian donors with detailed medical documentation. The overall purpose of the study was to identify expression quantitative trait loci (eQTL) in human liver for genes involved in absorption, distribution, metabolism and excretion of drugs, other xenobiotics, and endogenous substances.
Molecular sub-classification of hormone receptor-positive breast cancer
Study ID: EGAS00001004594
From a prospective, observational study of postmenopausal early breast cancer patients treated with tamoxifen or aromatase inhibitors gene expression analyses of 612 tumors was performed using the NanoString® Breast Cancer 360 panel comprising 770 genes across 23 key breast cancer pathways. Subgroups of patients have been identified with either an increased BRCAness signature expression associated with poor outcome, or high Tumor Inflammation Score associated with high tumor lymphocyte infiltration. The signatures may aid to select high-risk patients for combinatorial adjuvant treatment by targeting DNA repair deficiency or immune-checkpoints in addition to standard chemo-endocrine treatment.